Related references
Note: Only part of the references are listed.atg7-Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity
Yong Wang et al.
CIRCULATION RESEARCH (2021)
Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes
Xiaoxue Yu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity
Xiaoping Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission
Xinyue Liang et al.
PHARMACOLOGICAL RESEARCH (2020)
Enhanced mitophagy mediated by the YAP/Parkin pathway protects against DOX-induced cardiotoxicity
Dandan Xiao et al.
TOXICOLOGY LETTERS (2020)
Ethanol-Induced Mitochondrial Damage in Sertoli Cells is Associated with Parkin Overexpression and Activation of Mitophagy
Nabil Eid et al.
CELLS (2019)
Correction to Antiosteoporotic Activity of Harpagoside by Upregulation of the BMP2 and Wnt Signaling Pathways in Osteoblasts and Suppression of Differentiation in Osteoclasts (vol 80, pg 434, 2017)
Hwa-Jin Chung et al.
JOURNAL OF NATURAL PRODUCTS (2019)
Devil's claw (Harpagophytum procumbens) and chronic inflammatory diseases: A concise overview on preclinical and clinical data
Luigi Menghini et al.
PHYTOTHERAPY RESEARCH (2019)
SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function
Panxia Wang et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Multiple recycling routes: Canonical vs. non-canonical mitophagy in the heart
Alexandra Moyzis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)
Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
Stefania Gorini et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
Autophagic dysregulation in doxorubicin cardiomyopathy
Jordan J. Bartlett et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2017)
Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
Navid Koleini et al.
ONCOTARGET (2017)
Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis
Furqan Shaikh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis
Furqan Shaikh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky et al.
AUTOPHAGY (2016)
Triggering of Parkin Mitochondria! Translocation in Mitophagy: Implications for Liver Diseases
Nabil Eid et al.
FRONTIERS IN PHARMACOLOGY (2016)
A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission
Jing Zhou et al.
AUTOPHAGY (2015)
Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress
Paweorn Angsutararux et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2015)
Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms
Luc Rochette et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin
Jenelle Govender et al.
JOURNAL OF PINEAL RESEARCH (2014)
Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Filipa S. Carvalho et al.
MEDICINAL RESEARCH REVIEWS (2014)
The pathways of mitophagy for quality control and clearance of mitochondria
G. Ashrafi et al.
CELL DEATH AND DIFFERENTIATION (2013)
Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart
Atsushi Hoshino et al.
NATURE COMMUNICATIONS (2013)
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Yanti Octavia et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Harpagoside attenuates MPTP/MPP plus induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor
Xiaoyu Sun et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang et al.
NATURE MEDICINE (2012)
Different roles of p53 in the regulation of DNA damage caused by 1,2-heteroannelated anthraquinones and doxorubicin
Yung-Lung Chang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
p53 Regulates Oxidative Stress-Mediated Retrograde Signaling: A Novel Mechanism for Chemotherapy-Induced Cardiac Injury
Joyce M. Velez et al.
PLOS ONE (2011)
Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity
Masashi Yoshida et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Dexrazoxane (Totect (TM)): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy
Robert C. Kane et al.
ONCOLOGIST (2008)
Late anthracycline cardiotoxicity after childhood cancer - A prospective longitudinal study
K Sorensen et al.
CANCER (2003)